Blog
About

15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      PML targeting eradicates quiescent leukaemia-initiating cells.

      Nature

      metabolism, Adult, Animals, Arsenicals, pharmacology, therapeutic use, Cell Line, Coculture Techniques, Female, Gene Expression Regulation, Neoplastic, Hematopoietic Stem Cells, pathology, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Male, Mice, Mice, Inbred C57BL, Neoplastic Stem Cells, Nuclear Proteins, antagonists & inhibitors, deficiency, genetics, Oxides, Recurrence, Regeneration, Transcription Factors, Tumor Suppressor Proteins

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.

          Related collections

          Author and article information

          Journal
          10.1038/nature07016
          2712082
          18469801

          Comments

          Comment on this article